$PFE News You'd have to be a dope to buy marijuana stocks

New Post Public Reply Private Reply Replies (0) Message Board

Feb 20, 2014 at 11:43 AM

$PFE News

You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com
Pfizer, GE, Boeing lead early Dow advancers 9:34 a.m. Feb. 11, 2014 - William L. Watts
Judge likely to throw the book at Martoma, experts say 4:00 p.m. Feb. 6, 2014 - blogs.marketwatch.com
Feds, pharma rivals team up on Alzheimer's 2:32 p.m. Feb. 6, 2014 - blogs.marketwatch.com
The big Merck news centers on cancer-drug collaborations with other giants 11:02 a.m. Feb. 5, 2014 - blogs.marketwatch.com
Merck 4Q profit falls on weaker sales 8:21 a.m. Feb. 5, 2014 - MarketWatch.com
Stock market live blog: Indexes break 2-day losing streak; Kors, Yum climb 3:43 p.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow after an upgrade on promising cancer-drug tests 11:07 a.m. Feb. 4, 2014 - blogs.marketwatch.com
Pfizer leads Dow with 3% gain following upgrade 10:11 a.m. Feb. 4, 2014 - Russ Britt
Pfizer leads Dow with 3.3% gain following upgrade 10:03 a.m. Feb. 4, 2014 - Russ Britt
Pfizer advances 4.2% at the open, leads Dow 9:33 a.m. Feb. 4, 2014 - Victor Reklaitis
U.S. stocks see worst selloff in several months 4:41 p.m. Feb. 3, 2014 - Anora Mahmudova
Biggest drops since June for Dow industrials, S&P 500: stock market live blog recap 4:26 p.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer, Randgold gain in slumping stock market 3:52 p.m. Feb. 3, 2014 - Saumya Vaishampayan
Pfizer shares get a boost on positive results for breast-cancer treatment 10:37 a.m. Feb. 3, 2014 - blogs.marketwatch.com
Pfizer breast-cancer study meets endpoint 8:37 a.m. Feb. 3, 2014 - MarketWatch.com
The inscrutable gold timers 10:26 a.m. Jan. 30, 2014 - Mark Hulbert
Updates, advisories and surprises 5:31 p.m. Jan. 28, 2014 - MarketWatch
U.S. stocks rise; Dow breaks 5-day skid 5:02 p.m. Jan. 28, 2014 - Anora Mahmudova

Pfizer Inc (PFE): Today's Featured Drugs Laggard 5:01 p.m. Feb. 19, 2014 - TheStreet.com
Wall Street Winners: Were Analyst 2014 Picks Worth Their Salt? 8:53 a.m. Feb. 18, 2014 - Seeking Alpha
If Adam Smith Were Alive, He'd Be A Dividend Investor 6:51 a.m. Feb. 15, 2014 - Seeking Alpha
If Adam Smith Were Alive, He Would Be A Dividend Investor 6:51 a.m. Feb. 15, 2014 - Seeking Alpha
Dow Today: Pfizer (PFE) Leads The Day Higher, AT&T (T) Lags 10:00 a.m. Feb. 14, 2014 - TheStreet.com
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer Needs a Healthy Dose of Investor Love 6:00 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer's Finally a Buy 1:13 p.m. Feb. 13, 2014 - Barrons.com
10 Reasons To Buy Durect Right Now 10:45 a.m. Feb. 13, 2014 - Seeking Alpha
Australian regulator sues Pfizer over Lipitor sales tactics 9:58 a.m. Feb. 13, 2014 - Seeking Alpha
Pfizer Australia Faces Antitrust Probe 12:05 a.m. Feb. 13, 2014 - WSJ.com
Update on Bayer's Aleve - Analyst Blog 4:45 p.m. Feb. 12, 2014 - Zacks.com
Stock Market News for February 12, 2014 - Market News 10:06 a.m. Feb. 12, 2014 - Zacks.com
FDA News: Aleve Is Not Safer Than Advil, Ibuprofen & Celebrex 5:50 a.m. Feb. 12, 2014 - InvestorPlace.com
FDA Panel Rejects Changing Painkiller Labels 5:32 p.m. Feb. 11, 2014 - WSJ.com
Marginal Earnings Beat at Zoetis in Q4, Guidance Weak - Analyst Blog 10:57 a.m. Feb. 11, 2014 - Zacks.com
Zoetis Q4 Beats Estimates, But Guidance Hammers Stock 10:32 a.m. Feb. 11, 2014 - Investors Business Daily
Stock Market News for February 11, 2014 - Market News 10:06 a.m. Feb. 11, 2014 - Zacks.com
Pfizer Inc Stock Buy Recommendation Reiterated (PFE) 9:00 a.m. Feb. 11, 2014 - TheStreet.com
Zoetis Swings to Fourth-Quarter Profit 7:58 a.m. Feb. 11, 2014 - WSJ.com

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 10:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership 11:02 a.m. Feb. 13, 2014 - ACCESSWIRE
Northeast Shows Nearly $7 Billion in Reasons to Love the Life Science Industry's Capital Investments, an Industrial Info News Alert 6:15 a.m. Feb. 13, 2014 - Marketwire
Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees 2:03 p.m. Feb. 11, 2014 - BusinessWire - BZX
Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014 10:48 p.m. Feb. 4, 2014 - GlobeNewswire
LiveWorld and Pfizer to Present a Series of Panels on Social Media Within Regulated Industries at Social Media Week 10:00 a.m. Feb. 4, 2014 - BusinessWire - BZX
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market 9:05 a.m. Feb. 4, 2014 - PR Newswire - PRF
TrendingWallStreet.com Initiates Trend Analysis on GFOX, CMCSA, SKTO, and PFE 12:22 a.m. Feb. 4, 2014 - ACCESSWIRE
Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer 7:00 a.m. Feb. 3, 2014 - BusinessWire - BZX
Critical Alerts For Twitter, Alexion Pharmaceuticals, Pfizer, Ctrip, and AngloGold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 31, 2014 - PR Newswire - PRF
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results;Provides 2014 Financial Guidance 7:01 a.m. Jan. 28, 2014 - BusinessWire - BZX
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 7:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 8:00 a.m. Jan. 23, 2014 - BusinessWire - BZX
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating 10:00 a.m. Jan. 22, 2014 - BusinessWire - BZX
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 7:30 a.m. Jan. 22, 2014 - PR Newswire - PRF
CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 8:00 a.m. Jan. 21, 2014 - BusinessWire - BZX
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe 6:52 a.m. Jan. 21, 2014 - PR Newswire - PRF
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Jan. 17, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Eric Dalton: Redefining Homecare with Vision and Strategy

What's Behind Eric Dalton's Continued Recognition? Now, if you told me a healthcare leader’s named 'Visionary of the Year' twice in a row, my first thought isn't 'stretch goals' but 'show me the goods.' And that’s precisely what Eric J. Dalton has done. The Vice President at Angels on Call Homecare isn't just tooting his own horn; he's building a damn symphony in the...

Software Updates Costly: UX Not the Biggest Culprit

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

BD's New Liverty™ TIPS Stent: A Game Changer?

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

AppGate Rises as 2026 Leader in Digital Risk

AppGate: Forging a Path in Digital Security In a world where cyber threats seem to lurk around every digital corner, snagging the title of a leader in digital risk protection from the SPARK Matrix is no small feat. Let’s dive deep into AppGate’s rise to the top in QKS Group’s 2026 evaluation. What Sets AppGate Apart? AppGate's leadership status isn't some overnight...

McKinsey and Parloa Join Forces on AI Customer Service

AI-Revolutionizing Customer Service: The New Partnership Out of the boardroom and into the trenches, McKinsey joins hands with Parloa, aiming to reshape how enterprises handle customer service through artificial intelligence. Forget all the corporate fluff you've heard before; these guys are dead set on closing the massive gap companies face in deploying AI agents...

Fannie Mae Q3 2026 Earnings Surpass Expectations

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

BASIS Bellevue Expands with New K-4 Campus

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

BetaNXT and Pave Finance Transform Wealth Management

AI Takes Center Stage in Wealth Management You know, it's not every day we see two powerhouses like BetaNXT and Pave Finance buddying up to shake up the financial advisory world. This partnership's all about harnessing AI to give wealth management firms and financial advisors some serious firepower in portfolio planning. BetaNXT, already a big name with its slick...

Getlabs Brings GI Test Kits to Your Doorstep

By Logan Wright Updated Oct 28, 2026 Category News Views 106

Home Testing: A Game Changer for GI Patients Imagine dragging yourself out of bed, managing gut issues, only to face a grueling trip to a lab. It's the last thing a patient with GI symptoms wants. Enter Getlabs and Genova Diagnostics with a welcome shift: a partnership that promises to bring the lab to your doorstep—literally. The Partnership Expansion Getlabs, the...